Abidali, M., St Victor, G., Mashaly, S., & Dahal, P. (2024). Red kratom and red corvette: A case of mania induced by kratom withdrawal. The International Journal of Psychiatry in Medicine, 60(2), 221–225. doi:10.1177/00912174241281980
Afzal, H., Esang, M., & Rahman, S. (2020). A case of kratom-induced seizures. Cureus. doi:10.7759/cureus.6588
Ahmad, J., Odin, J. A., Hayashi, P. H., Fontana, R. J., Conjeevaram, H., Avula, B., Khan, I. A., Barnhart, H., Vuppalanchi, R., & Navarro, V. J. (2021). Liver injury associated with kratom, a popular opioid-like product: Experience from the U.S. drug induced liver injury network and a review of the literature. Drug and Alcohol Dependence, 218. doi:10.1016/j.drugalcdep.2020.108426
Ahmad, K., & Aziz, Z. (2012). Mitragyna speciosa use in the northern states of Malaysia: A cross-sectional study. Journal of Ethnopharmacology, 141(1), 446–450. doi:10.1016/j.jep.2012.03.009
Ahmed, S., Tran, Q. V., & McLean, M. (2023). The great imitator: A case of accidental kratom overdose. Cureus. doi:10.7759/cureus.43144
Alameh, I., Lebedev, M. V., Clark, J. M., Kamareddine, M., Ferrara, D., DeLorenzo, O., Sidhu, B. V., & Heric, A. (2025). Kratom-associated acute right ventricular dysfunction. JACC: Case Reports, 30(20). doi:10.1016/j.jaccas.2025.104206
Allison, D. R., Mubarak, M., Sharma, N., & Rao, D. S. (2022). Kratom (mitragyna speciosa)-induced hepatitis. ACG Case Reports Journal, 9(4). doi:10.14309/crj.0000000000000715
Alsarraf, E., Myers, J., Culbreth, S., & Fanikos, J. (2019). Kratom from head to toe—case reviews of adverse events and toxicities. Current Emergency and Hospital Medicine Reports, 7(4), 141–168. doi:10.1007/s40138-019-00194-1
Anand, A., & Hosanagar, A. (2022). The addictive potential and challenges with use of the “herbal supplement” kratom: A case report and literature review. Pain Medicine, 23(1), 4–9. doi:10.1093/pm/pnab126
Anderer, S. (2025). What to know about 7-OH, the new vape shop hazard. Jama, 334(12). doi:10.1001/jama.2025.13592
Awad, M., Burke, H. H., & Oakman, S. A. (2024). Kratom-induced psychiatric decompensation and paranoid delusions. Cureus. doi:10.7759/cureus.54626
Bachu, A. K., Singal, P., Griffin, B., Harbaugh, L., Prasad, S., Jain, L., Mohiuddin, S., Papudesi, B. N., Nagi, T., Youssef, N. A., Chopra, A., & Ahmed, S. (2023). Kratom use and mental health: A systematic literature review and case example. Journal of Addictive Diseases, 42(4), 301–312. doi:10.1080/10550887.2023.2273192
Begum, T., Arzmi, M. H., Helal Uddin, A. B. M., Khatib, A., Abbas, S. A., & Ahmed, Q. U. (2024). Mitragyna speciosa korth toxicity: Experimental findings and future prospects. Journal of Taibah University Medical Sciences, 19(6), 1143–1156. doi:10.1016/j.jtumed.2024.12.002
Behonick, G. S., Vu, C., Czarnecki, L., El-Ters, M., & Shanks, K. G. (2022). Two single-drug fatal intoxications by mitragynine. Journal of Analytical Toxicology, 46(5), e110–e114. doi:10.1093/jat/bkac016
Bleifuss, W., Boley, S., Bardwell, J., Goebel, C., & Wilkinson, J. (2025). Severe kava withdrawal managed with phenobarbital. The American Journal of Emergency Medicine. doi:10.1016/j.ajem.2025.06.016
Botejue, M., Walia, G., Shahin, O., Sharma, J., & Zackria, R. (2021). Kratom-induced liver injury: A case series and clinical implications. Cureus. doi:10.7759/cureus.14679
Bowe, A., & Kerr, P. L. (2020). A complex case of kratom dependence, depression, and chronic pain in opioid use disorder: Effects of buprenorphine in clinical management. Journal of Psychoactive Drugs, 52(5), 447–452. doi:10.1080/02791072.2020.1773586
Brogdon, H. D., McPhee, M. M., Paine, M. F., Cox, E. J., & Burns, A. G. (2022). A case of potential pharmacokinetic kratom-drug interactions resulting in toxicity and subsequent treatment of kratom use disorder with buprenorphine/naloxone. Journal of Addiction Medicine, 16(5), 606–609. doi:10.1097/adm.0000000000000968
Broul, M., Rudenko, X., Bajus, A., Král, J., Kyenge, D. M., Staňková, Z., & Albrecht, J. (2025). Case report: Cannabis and kratom-induced self-amputation of ears and penis. Frontiers in Psychiatry, 16. doi:10.3389/fpsyt.2025.1479863
Brown, P. N., Lund, J. A., & Murch, S. J. (2017). A botanical, phytochemical and ethnomedicinal review of the genus Mitragyna korth: Implications for products sold as kratom. Journal of Ethnopharmacology, 202, 302–325. doi:10.1016/j.jep.2017.03.020
Burke, D. J., Mahonski, S. G., & Van Cott, A. C. (2021). Breakthrough seizure associated with kratom use in patients with epilepsy. Neurology Clinical Practice, 11(1), 78–84. doi:10.1212/cpj.0000000000000846
Chichagi, F., Alikhani, R., & Beigi Harchegani, A. (2023). Cardiovascular health in kratom users: A narrative review. Journal of Addictive Diseases, 42(4), 313–325. doi:10.1080/10550887.2023.2282033
Cinosi, E., Martinotti, G., Simonato, P., Singh, D., Demetrovics, Z., Roman-Urrestarazu, A., Bersani, F. S., Vicknasingam, B., Piazzon, G., Li, J. H., Yu, W. J., Kapitány-Fövény, M., Farkas, J., Di Giannantonio, M., & Corazza, O. (2015). Following “the roots” of kratom (mitragyna speciosa): The evolution of an enhancer from a traditional use to increase work and productivity in Southeast Asia to a recreational psychoactive drug in Western countries. BioMed Research International, 2015, 1–11. doi:10.1155/2015/968786
Colucci, S., Culbreth, S., Alsarraf, E., & Fanikos, J. (2019). Why does the Food and Drug Administration need to ban kratom? Current Emergency and Hospital Medicine Reports, 7(4), 169–174. doi:10.1007/s40138-019-00201-5
Corkery, J. M., Streete, P., Claridge, H., Goodair, C., Papanti, D., Orsolini, L., Schifano, F., Sikka, K., Körber, S., & Hendricks, A. (2019). Characteristics of deaths associated with kratom use. Journal of Psychopharmacology, 33(9), 1102–1123. doi:10.1177/0269881119862530
Cutlip, H. A., Bushman, E., Thottumari, L., Mogallapu, R., & Ang-Rabanes, M. (2021). A case report of kratom-induced psychosis. Cureus. doi:10.7759/cureus.16073
Dasgupta, A., & Ye, Z. (2024). Severe jaundice with life-threatening liver failure after kratom use: Reversed by plasma exchange. Transfusion and Apheresis Science, 63(3). doi:10.1016/j.transci.2024.103898
Davidson, L., Rawat, M., Stojanovski, S., & Chandrasekharan, P. (2018). Natural drugs, not so natural effects: Neonatal abstinence syndrome secondary to ‘kratom’. Journal of Neonatal-Perinatal Medicine, 12(1), 109–112. doi:10.3233/npm-1863
Devitt, S. (2025). Health advisory: Serious illnesses associated with 7-OH use. America’s Poison Centers. https://poisoncenters.org/news-alerts/13531044
Dhoble, L. R., Gour, A., McCurdy, C. R., & Sharma, A. (2025). Evaluating the drug interactions in kratom usage: Clinical application. Expert Opinion on Drug Metabolism & Toxicology, 21(8), 949–959. doi:10.1080/17425255.2025.2521045
Dodulík, J., Plášek, J., Handlos, P., Gřegořová, A., Václavík, J., Badertscher, P., Ahmed, N., Galyavich, A., Carazo, C. M., & Bensaaud, A. (2024). Ventricular fibrillation during football training as a consequence of kratom and caffeine use in an adolescent: Case report. European Heart Journal - Case Reports, 8(8). doi:10.1093/ehjcr/ytae364
Eastlack, S. C., Cornett, E. M., & Kaye, A. D. (2020). Kratom—Pharmacology, clinical implications, and outlook: A comprehensive review. Pain and Therapy, 9(1), 55–69. doi:10.1007/s40122-020-00151-x
Edinoff, A. N., Kaufman, S. E., Mahoney, T. C., Upshaw, W. C., Gong, J., Cornett, E. M., Murnane, K. S., Kaye, A. M., Varrassi, G., Shekoohi, S., & Kaye, A. D. (2024). Kratom: A narrative review of the possible clinical uses and dangers of this opioid-like plant. Cureus. doi:10.7759/cureus.73058
Eldridge, W. B., Foster, C., & Wyble, L. (2018). Neonatal abstinence syndrome due to maternal kratom use. Pediatrics, 142(6). doi:10.1542/peds.2018-1839
Eudaley, S. T., Brooks, S. P., & Hamilton, L. A. (2022). Case report: Possible serotonin syndrome in a patient taking kratom and multiple serotonergic agents. Journal of Pharmacy Practice, 36(6), 1523–1527. doi:10.1177/08971900221116009
Garcia-Romeu, A., Cox, D. J., Smith, K. E., Dunn, K. E., & Griffiths, R. R. (2020). Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic. Drug and Alcohol Dependence, 208. doi:10.1016/j.drugalcdep.2020.107849
Gershman, K., Timm, K., Frank, M., Lampi, L., Melamed, J., Gerona, R., & Monte, A. A. (2019). Deaths in Colorado attributed to kratom. New England Journal of Medicine, 380(1), 97–98. doi:10.1056/NEJMc1811055
Hall, A., & Hall, D. (2021). Kratom ingestion and emergency care: Summary and a case report. Journal of Emergency Nursing,47(4), 551–556. doi:10.1016/j.jen.2021.02.004
Hemby, S. E., McIntosh, S., Leon, F., Cutler, S. J., & McCurdy, C. R. (2018). Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7‐hydroxymitragynine. Addiction Biology, 24(5), 874–885. doi:10.1111/adb.12639
Henningfield, J. E., Grundmann, O., Huestis, M. A., & Smith, K. E. (2024). Kratom safety and toxicology in the public health context: Research needs to better inform regulation. Frontiers in Pharmacology, 15. doi:10.3389/fphar.2024.1403140
Hill, K., Boyer, E. W., Grundmann, O., & Smith, K. E. (2025). De facto opioids: Characterization of novel 7-hydroxymitragynine and mitragynine pseudoindoxyl product marketing. Drug and Alcohol Dependence, 272. doi:10.1016/j.drugalcdep.2025.112701
Holton, K., Sanchez Corredera, C., Haidar, J., Valentin, R. G., Perez, D., & Boccio, E. (2024). Acquired type 1 brugada syndrome induced by chronic high-dose kratom use. Cureus. doi:10.7759/cureus.72129
Hughes, R. L. (2018). Fatal combination of mitragynine and quetiapine – A case report with discussion of a potential herb-drug interaction. Forensic Science, Medicine and Pathology, 15(1), 110–113. doi:10.1007/s12024-018-0049-9
Jarka, C., & Gregoire, K. (2023). Precipitated withdrawal with kratom use following naltrexone administration. Mental Health Clinician, 13(3), 155–158. doi:10.9740/mhc.2023.06.155
Jensen, A. N., Truong, Q. N., Jameson, M., & Nadal, C. N. (2021). Kratom-induced transaminitis with subsequent precipitated opioid withdrawal following naltrexone. Mental Health Clinician, 11(3), 220–224. doi:10.9740/mhc.2021.05.220
Kerrigan, S., & Basiliere, S. (2021). Kratom: A systematic review of toxicological issues. WIREs Forensic Science, 4(1). doi:10.1002/wfs2.1420
Khan, M. Z., Saleh, M. A., Alkhayyat, M., Roberts, D. E., & Lindenmeyer, C. C. (2021). Multiorgan dysfunction related to kratom ingestion. ACG Case Reports Journal, 8(8). doi:10.14309/crj.0000000000000647
Kruegel, A. C., Uprety, R., Grinnell, S. G., Langreck, C., Pekarskaya, E. A., Le Rouzic, V., Ansonoff, M., Gassaway, M. M., Pintar, J. E., Pasternak, G. W., Javitch, J. A., Majumdar, S., & Sames, D. (2019). 7-hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects. ACS Central Science, 5(6), 992–1001. doi:10.1021/acscentsci.9b00141
LeSaint, K. T., Yin, S., Sharma, A., Avery, B. A., McCurdy, C. R., & Waksman, J. C. (2022). Acute renal insufficiency associated with consumption of hydrocodone- and morphine-adulterated kratom (mitragyna speciosa). The Journal of Emergency Medicine, 63(1), e28–e30. doi:10.1016/j.jemermed.2022.02.004
Lovrecic, B., Lovrecic, M., Gabrovec, B., Carli, M., Pacini, M., Maremmani, A. G. I., & Maremmani, I. (2019). Non-medical use of novel synthetic opioids: A new challenge to public health. International Journal of Environmental Research and Public Health, 16(2). doi:10.3390/ijerph16020177
Lydecker, A. G., Sharma, A., McCurdy, C. R., Avery, B. A., Babu, K. M., & Boyer, E. W. (2016). Suspected adulteration of commercial kratom products with 7-hydroxymitragynine. Journal of Medical Toxicology, 12(4), 341–349. doi:10.1007/s13181-016-0588-y
McCurdy, C. R., Sharma, A., Smith, K. E., Veltri, C. A., Weiss, S. T., White, C. M., & Grundmann, O. (2024). An update on the clinical pharmacology of kratom: Uses, abuse potential, and future considerations. Expert Review of Clinical Pharmacology, 17(2), 131–142. doi:10.1080/17512433.2024.2305798
Meireles, V., Rosado, T., Barroso, M., Soares, S., Gonçalves, J., Luís, Â., Caramelo, D., Simão, A. Y., Fernández, N., Duarte, A. P., & Gallardo, E. (2019). Mitragyna speciosa: Clinical, toxicological aspects and analysis in biological and non-biological samples. Medicines, 6(1). doi:10.3390/medicines6010035
Miller, A. H. F., Krotulski, A. J., Walton, S. E., Dulaney, A. R., Frolichstein, A. P., Dusek, H. L., & Murphy, C. (2025). Kratom cardiotoxicity. JACC: Case Reports, 30(5). doi:10.1016/j.jaccas.2024.103109
Nacca, N., Schult, R. F., Li, L., Spink, D. C., Ginsberg, G., Navarette, K., & Marraffa, J. (2019). Kratom adulterated with phenylethylamine and associated intracerebral hemorrhage: Linking toxicologists and public health officials to identify dangerous adulterants. Journal of Medical Toxicology, 16(1), 71–74. doi:10.1007/s13181-019-00741-y
Nellhaus, E., Andrews, L., Haas, J., Miskell, D., Kurek, K., Hansen, Z., & Davies, T. H. (2018). Neonatal withdrawal following in utero exposure to kratom. International Journal of Clinical Pediatrics, 7(4), 55–58. doi:10.14740/ijcp317w
O’Malley Olsen, E., O’Donnell, J., Mattson, C. L., Schier, J. G., & Wilson, N. (2019). Notes from the field: Unintentional drug overdose deaths with kratom detected — 27 states, July 2016–December 2017. MMWR. Morbidity and Mortality Weekly Report, 68(14), 326–327. doi:10.15585/mmwr.mm6814a2
Osborne, C. S., Overstreet, A. N., Rockey, D. C., & Schreiner, A. D. (2019). Drug-induced liver injury caused by kratom use as an alternative pain treatment amid an ongoing opioid epidemic. Journal of Investigative Medicine High Impact Case Reports, 7. doi:10.1177/2324709619826167
Overbeek, D., Abraham, J., & Munzer, B. (2019). Kratom (mitragynine) ingestion requiring naloxone reversal. Clinical Practice and Cases in Emergency Medicine, 3(1), 24–26. doi:10.5811/cpcem.2018.11.40588
Patel, P., Aknouk, M., Keating, S., Richard, I., Kata, P., Ali, R. Y., & Cheriyath, P. (2021). Cheating death: A rare case presentation of kratom toxicity. Cureus. doi:10.7759/cureus.16582
Prevete, E., Theunissen, E. L., Kuypers, K. P. C., Paci, R., Reckweg, J. T., Cavarra, M., Toennes, S. W., Ritscher, S., Bersani, G., Corazza, O., Pasquini, M., & Ramaekers, J. G. (2024). An exploratory study of the safety profile and neurocognitive function after single doses of mitragynine in humans. Psychopharmacology, 242(6), 1363–1376. doi:10.1007/s00213-024-06734-2
Prozialeck, W. C., Avery, B. A., Boyer, E. W., Grundmann, O., Henningfield, J. E., Kruegel, A. C., McMahon, L. R., McCurdy, C. R., Swogger, M. T., Veltri, C. A., & Singh, D. (2019). Kratom policy: The challenge of balancing therapeutic potential with public safety. International Journal of Drug Policy, 70, 70–77. doi:10.1016/j.drugpo.2019.05.003
Raffa, R. B., Pergolizzi, J. V., Taylor, R., & Ossipov, M. H. (2018). Nature's first “atypical opioids”: Kratom and mitragynines. Journal of Clinical Pharmacy and Therapeutics, 43(3), 437–441. doi:10.1111/jcpt.12676
Ramachandram, D. S., Damodaran, T., Zainal, H., Murugaiyah, V., & Ramanathan, S. (2020). Pharmacokinetics and pharmacodynamics of mitragynine, the principle alkaloid of Mitragyna speciosa: Present knowledge and future directions in perspective of pain. Journal of Basic and Clinical Physiology and Pharmacology, 31(1). doi:10.1515/jbcpp-2019-0138
Rao, A. K., Lee, T. J., & Bodle, J. (2025). Bilateral hippocampal toxicity in a patient using kratom. BMJ Case Reports, 18(1). doi:10.1136/bcr-2024-262213
Ratard, R. (2019). Kratom (Mitragyna speciose) study: On the public health risks and recommendations. https://www.ldh.la.gov/assets/docs/LegisReports/HR177RS2018219.pdf
Roma, K., Mohammed, S., Sieck, B., Naik, K., & Wahid, S. (2023). Kratom-induced acute liver injury: A case study and the importance of herbal supplement regulation. Journal of Hepatology, 79(2), 581–584. doi:10.1016/j.jhep.2023.04.026
Sablaban, I. M., & Gautam, M. (2020). The diagnosis of severe obsessions in the setting of kratom withdrawal and treatment with lorazepam: Case report. Journal of Addictive Diseases, 39(1), 138–139. doi:10.1080/10550887.2020.1813357
Sangani, V., Sunnoqrot, N., Gargis, K., Ranabhotu, A., Mubasher, A., & Pokal, M. (2021). Unusual presentation of kratom overdose with rhabdomyolysis, transient hearing loss, and heart failure. Journal of Investigative Medicine High Impact Case Reports, 9. doi:10.1177/23247096211005069
Schimmel, J., & Dart, R. C. (2020). Kratom (Mitragyna speciosa) liver injury: A comprehensive review. Drugs, 80(3), 263-283. doi:10.1007/s40265-019-01242-6
Sethi, R., Hoang, N., Ravishankar, D. A., McCracken, M., & Manzardo, A. M. (2020). Kratom (Mitragyna speciosa). The Primary Care Companion For CNS Disorders, 22(1). doi:10.4088/PCC.19nr02507
Settle, A. G., & Yang, C. (2022). A case of severe kratom addiction contributing to a suicide attempt. Cureus. doi:10.7759/cureus.29698
Shi, T., & Shea, J. L. (2023). A case of fatal overdose involving both hydromorphone and kratom. Journal of Forensic Sciences, 69(1), 355–358. doi:10.1111/1556-4029.15394
Singh, D., Damodaran, T., Prozialeck, W. C., Grundmann, O., Karunakaran, T., & Vicknasingam, B. (2018). Constipation prevalence and fatigue severity in regular kratom (Mitragyna speciosa korth) users. Journal of Substance Use, 24(3), 233-239. doi:10.1080/14659891.2018.1546340
Smith, K. E., Boyer, E. W., Grundmann, O., McCurdy, C. R., & Sharma, A. (2024). The rise of novel, semi‐synthetic 7‐hydroxymitragynine products. Addiction, 120(2), 387–388. doi:10.1111/add.16728
Spetea, M., & Schmidhammer, H. (2019). Unveiling 7-hydroxymitragynine as the key active metabolite of mitragynine and the promise for creating novel pain relievers. ACS Central Science, 5(6), 936–938. doi:10.1021/acscentsci.9b00462
Stanciu, C. N., Gnanasegaram, S. A., Ahmed, S., & Penders, T. (2019). Kratom withdrawal: A systematic review with case series. Journal of Psychoactive Drugs, 51(1), 12–18. doi:10.1080/02791072.2018.1562133
Suhaimi, F. W., Yusoff, N. H. M., Hassan, R., Mansor, S. M., Navaratnam, V., Müller, C. P., & Hassan, Z. (2016). Neurobiology of kratom and its main alkaloid mitragynine. Brain Research Bulletin, 126, 29–40. doi:10.1016/j.brainresbull.2016.03.015
Tanna, R. S., Cech, N. B., Oberlies, N. H., Rettie, A. E., Thummel, K. E., & Paine, M. F. (2023). Translating kratom-drug interactions: From bedside to bench and back. Drug Metabolism and Disposition, 51(8), 923–935. doi:10.1124/dmd.122.001005
Tassavor, B., Young Eun, C., Nikolskaia, O., & Jobarteh-Williams, R. (2025). Hyperpigmentation from chronic kratom use: A case report and review of the literature. Cureus. doi:10.7759/cureus.79804
Tatum, W. O., Hasan, T. F., Coonan, E. E., & Smelick, C. P. (2018). Recurrent seizures from chronic kratom use, an atypical herbal opioid. Epilepsy & Behavior Case Reports, 10, 18–20. doi:10.1016/j.ebcr.2018.04.002
Tayabali, K., Bolzon, C., Foster, P., Patel, J., & Kalim, M. O. (2018). Kratom: A dangerous player in the opioid crisis. Journal of Community Hospital Internal Medicine Perspectives, 8(3), 107–110. doi:10.1080/20009666.2018.1468693
Thewjitcharoen, Y., Krittiyawong, S., Nakasatien, S., & Himathongkam, T. (2022). Kratom-associated mixed cholestatic-hepatocellular liver injury in a patient with long COVID: A case report. Clinical Medicine Insights: Case Reports, 15. doi:10.1177/11795476221132824
Tobarran, N., Wolf, C., Cumpston, K. L., & Wills, B. K. (2022). Pressure necrosis requiring fasciotomy after kratom overdose. Journal of Addiction Medicine, 16(2), 252–253. doi:10.1097/adm.0000000000000873
Torres-Ortiz, A., Al Zein, S., & Alqudsi, M. (2022). A case of hyperkalemia induced by kratom (Mitragyna speciosa). Cureus. doi:10.7759/cureus.24036
U.S. Food & Drug Administration. (2025). 7-hydroxymitragynine (7-OH): An assessment of the scientific data and toxicological concerns around an emerging opioid threat. https://www.fda.gov/media/187899/download?attachment
Vadiei, N., Evoy, K. E., & Grundmann, O. (2025). The impact of diverse kratom products on use patterns, dependence, and toxicity. Current Psychiatry Reports, 27(10), 584–592. doi:10.1007/s11920-025-01631-7
Vanani, N. B., Stevanovic, S. G., & Stevanovic, N. (2023). Adverse drug interaction between kratom and amitriptyline with gastrointestinal and mild hepatic effects. Cureus. doi:10.7759/cureus.33809
Veltri, C. A., & Grundmann, O. (2019). Current perspectives on the impact of Kratom use. Substance Abuse and Rehabilitation, Volume 10, 23–31. doi:10.2147/sar.S164261
Webb, M., Isenschmid, D. S., Sung, L., Hlavaty, L., & Gupta, A. (2019). Kratom: The herbal opioid. Journal of Clinical Toxicology, 9(4).
Woo, S. M., Davis, W. D., Aggarwal, S., Clinton, J. W., Kiparizoska, S., & Lewis, J. H. (2021). Herbal and dietary supplement induced liver injury: Highlights from the recent literature. World Journal of Hepatology, 13(9), 1019–1041. doi:10.4254/wjh.v13.i9.1019